

# BMJ Open *Helicobacter pylori* infection in patients with inflammatory bowel diseases: a single-centre, prospective, observational study in Egypt

Ekram W. Abd El-Wahab <sup>1</sup>, Ebtessam I. Youssef,<sup>1</sup> Ehab Hassouna<sup>2</sup>

**To cite:** Abd El-Wahab EW, Youssef EI, Hassouna E. *Helicobacter pylori* infection in patients with inflammatory bowel diseases: a single-centre, prospective, observational study in Egypt. *BMJ Open* 2022;**12**:e057214. doi:10.1136/bmjopen-2021-057214

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-057214>).

Received 08 September 2021  
Accepted 13 April 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Tropical Health Department, High Institute of Public Health, Alexandria University, 21561 Alexandria, Egypt

<sup>2</sup>Internal Medicine Department, Faculty of Medicine, Alexandria University, 21568 Alexandria, Egypt

## Correspondence to

Dr Ekram W. Abd El-Wahab; [ekram.wassim@alexu.edu.eg](mailto:ekram.wassim@alexu.edu.eg)

## ABSTRACT

**Objective** Conflicting results have been reported by numerous epidemiological studies investigating the association between *Helicobacter pylori* (*H. pylori*) infection and inflammatory bowel disease (IBD). We aimed in this study to assess the possible association between *H. pylori* infection and IBD and its effects on disease progression.

**Design** Prospective observational study.

**Setting** Specialised IBD care clinics at Alexandria University Student Hospital in northern Egypt, between March and June 2019.

**Participants** 182 patients with IBD.

**Analysis and outcome measures** Participants with IBD were screened for *H. pylori* infection and clinically evaluated at the initial visit and bimonthly for 3 months to record any potential improvement/flare of the IBD condition.

**Results** Overall, 90 (49.5%) patients with IBD had evidence of *H. pylori* infection. The course of IBD did not significantly differ in association with *H. pylori* infection or IBD treatment strategy. Cox regression analysis revealed that patients aged 20–35 years (HR=6.20 (95% CI: 1.74 to 22.12)) and 35–55 years (557.9 (17.4–17 922.8)), high socioeconomic status (2.9 (1.11–7.8)), daily consumption of fibre-rich food (5.1 (1.32–19.5)), occasional consumption of snacks between meals (2.8 (2.5–70.5)) and eating four meals per day (13.3 (1.0–7.7)) were predictive of IBD flare. By contrast, eating fruits and vegetables showed a strongly protective association (HR=0.001 (95% CI: 0.0002 to 0.02)). The probabilities of improvement of IBD symptoms after 12 weeks of follow-up were comparable in assessments based on *H. pylori* infection status (0.793 for *H. pylori* negative vs 0.778 for *H. pylori* positive) and IBD treatment option (0.811 for conventional therapy vs 0.750 for biological therapy).

**Conclusion** The association between IBD and *H. pylori* infection is unresolved and should be further investigated in the context of specific environmental exposures that can influence the development or relapse of IBD.

## INTRODUCTION

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), comprises chronic, disabling and progressive disorders characterised by life-long treatment that imposes a significant

## Strengths and limitations of this study

- ⇒ We were able to report the effect of *Helicobacter pylori* (*H. pylori*) infection on the response to conventional versus biological treatment of inflammatory bowel disease (IBD).
- ⇒ The relatively small sample size and single-centre setting may limit the generalisability of the results.
- ⇒ The study lacks a non-IBD healthy control group, and a causal link between *H. pylori* infection and IBD cannot be established.
- ⇒ Estimating the prevalence of *H. pylori* in patients with IBD was limited by the detection method.

globally increasing threat to human health.<sup>1</sup> Numerous economically low-income countries have experienced a dramatic increase in the incidence of IBD.<sup>2</sup> Improved access to a more hygienic environment and the resulting decreased incidence of common childhood infections may represent a contributing factor through altering susceptibility to diseases with an autoimmune component, such as IBD.<sup>3 4</sup> Accordingly, microbial infections during childhood may protect against IBD. This rise may partially be accounted for by the implementation of improved diagnostic methods and heightened awareness of IBD.

Although the pathogenesis of IBD is unknown, evidence indicates that it involves complex and unidentified interactions between environmental factors (such as infections, medicines, tobacco, food components) as well as host genetic factors that induce abnormal or inappropriate immunological reactions, or both, to components of the intestinal flora.<sup>5 6</sup>

Evidence indicates that *Helicobacter pylori* (*H. pylori*) resides in the upper gastrointestinal tract of approximately 50% of the world's population, among which >80% of people lack symptoms.<sup>7</sup> In Egypt, the prevalence is

approximately 80%.<sup>8</sup> *H. pylori* can elicit a chronic systemic inflammatory response, which may trigger autoimmune reactions that may contribute to the pathogenesis of autoimmune diseases. The inflammatory response of the gastric mucosa mainly involves stimulation of the host's immune system in response to *H. pylori*, which induces a cell-mediated immune response characterised by elevated levels of cytokines. Consequently, products of local immune reactions may migrate to extragastric sites, which may account for the association between *H. pylori* infection and extragastric diseases, including autoimmune disorders.<sup>9</sup>

Although numerous, diverse studies analysed the association between *H. pylori* infection and IBD,<sup>9–10</sup> a causal association between *H. pylori* and IBD remains to be established; and the are contradictory data related to the potential causative and the protective roles of *H. pylori* infection associated with IBD.<sup>11–19</sup>

Assuming a potential protective role of *H. pylori* infection against IBD, *H. pylori* eradication treatment may influence the progression of IBD course and thus should be carefully administered, considering the findings of future prospective studies.<sup>16–20</sup>

IBD occurs more frequently in regions with lower rates of *H. pylori* colonisation. The steady increase in the incidence of IBD in *H. pylori*-endemic regions may reflect the advent of initiating anti-*H. pylori* therapy to treat peptic ulcers.<sup>13</sup> Furthermore, meta-analyses show that the prevalence of *H. pylori* infection is lower in patients with IBD compared with controls.<sup>9–10, 13, 19, 21</sup> For example, long-term treatment with sulphasalazine contributes to the eradication of *H. pylori* infection.<sup>22</sup> Although unconfirmed, most studies indicate a protective role for *H. pylori* infection against the development of IBD.<sup>9, 21</sup>


With advances in identifying the pathological mechanisms underlying IBD, new therapies have been proposed, particularly those involving biological response modifiers. These include antitumour necrosis factor antibodies (anti-TNF- $\alpha$ , anti-tumour necrosis factor alpha), interleukin-1 (IL-1)/IL-6 receptor antagonists and an anti-CD20 antibody. These therapies are generally well tolerated, although they may be associated with adverse effects, including increased susceptibility to infection and increased risk of malignancies.<sup>23</sup>

These considerations inspired us to conduct a prospective, longitudinal study to further analyse the association between *H. pylori* infection and the flare of IBD and to investigate possible effects of *H. pylori* infection on the response to conventional versus biological treatment of IBD.

## METHODS

### Study population and sampling

We conducted a prospective observational study at Alexandria University Student Hospital (AUSH) that is affiliated with Alexandria University, Egypt and serves students, faculty and staff members. AUSH comprises outpatient



**Figure 1** Patient dispositions. EIA, enzyme immunoassay; IBD, inflammatory bowel disease.

clinics and inpatient and emergency departments with a bed capacity of 1000. We enrolled patients aged  $\geq 18$  years with confirmed IBD (triphasic CT abdomen, endoscopy/colonoscopy and faecal calprotectin) and commenced IBD treatment (conventional or biological). Patients with irritable bowel syndrome were excluded according to the Rome III criteria.<sup>24</sup>

Clinicians on the staff of the Internal Medicine Department of the AUSH selected the treatment (standard vs biological). The prescribed treatment is the standard of care adopted by the AUSH for treating patients with IBD. Details of the treatment regimens and the parameters employed to select standard or biological treatment are described in online supplemental file S1.

The frequency of *H. pylori* infection among patients with IBD is as high as 10.0%.<sup>21</sup> Using a margin of error=5.0%, an alpha error=0.05 and a 95% CI level, the minimum required sample size was 138.<sup>8</sup> However, we ultimately enrolled 182 patients with IBD, because we expected that the prevalence of *H. pylori* infection might be higher because of the endemicity of *H. pylori* infection in Egypt,<sup>8</sup> and to compensate for possible dropouts during the follow-up. The sample size was calculated using Epi info V.7 software. Patients with confirmed IBD who agreed to participate in the study were consecutively enrolled. According to their characteristics (figure 1), the patients were assigned into groups according to the prescribed treatment regimen (online supplemental file S1) as follows: Group 1 comprised patients administered conventional IBD treatment, and Group 2 included patients undergoing biological IBD treatment.

Stool samples was used to detect *H. pylori* antigen using a commercially available enzyme immunoassay (EIA) kit (Foresight EIA test kit for qualitative and quantitative detection of *H. pylori* in the stool; ACON Laboratories, Inc, San Diego, California, USA). Each assigned group included patients with IBD with or without *H. pylori* infection, and patients who were *H. pylori*-positive were shown their laboratory findings. We did not commence *H. pylori* eradication therapy during the study period. After a 3-month follow-up, patients who were *H. pylori*-positive were referred to a specialist for further evaluation and case management according to the adopted standard of care.

## Patient and public involvement

We informed the patients about the aims and concerns of the study and how it will add to better understanding of their disease aetiology and triggering factors, which was highly appreciated by the patients, and motivated them to be a part of the cohort intended for the long-term follow-up by the clinicians. However, it was not appropriate or possible to involve patients or the public in the design, conduct, reporting or dissemination plans of our research. All the laboratory and clinical data were reported to the study participants, where we discussed the study findings in a simple language.

## Assessments

Baseline evaluation included the patient's history, full clinical examination and laboratory tests. A data collection form (online supplemental file S2) was used to collect baseline data as follows: sociodemographic characteristics, personal habits, lifestyle, physical activity and exercise, dietary habits and restrictions, family history, medical history, comorbidities and medications. Clinical data collected from each patient during the initial visit are as follows: disease onset, history of present complaints, frequency and duration of IBD attacks, past and current IBD medications, history of changing therapy, surgical intervention and complications. History of *H. pylori* infection and undergoing *H. pylori* eradication therapy during the past 12 months were recorded during each follow-up visit. All patients were followed bimonthly for 3 months (six visits) during IBD treatment. Patients were contacted weekly via telephone and asked about the frequency and severity of symptoms and if adverse effects associated with treatment occurred during the previous week.

Blood pressure (BP) and anthropometric measurements were measured according to standard techniques.<sup>25–27</sup> Body mass index (BMI) was calculated according to the Quetelet's index:  $BMI = (\text{weight (kg)} / \text{height}^2 (\text{m}^2))$ . At each follow-up visit, laboratory tests were performed as follows: complete blood count, C reactive protein (CRP), erythrocyte sedimentation rate (ESR), fasting blood glucose (FBG) and faecal calprotectin.<sup>28</sup> Imaging techniques included triphasic CT and endoscopy/colonoscopy when indicated. All patients underwent full-length colonoscopy (Pentax colonoscopies). Colonoscopic biopsies were acquired from the rectum and sigmoid; descending, transverse, ascending colon; as well as the cecal mucosa. Histological analyses of the degree of inflammation associated with CD and UC were evaluated according to the European consensus on the histopathology of IBD.<sup>29</sup>

The socioeconomic status of the enrolled patients with IBD was calculated and categorised as high, middle, low and very low, according to a modified social scoring system.<sup>30</sup>

## Outcomes

Patients in each group were clinically evaluated every 2 weeks for 3 months to record potential improvement/

flare of IBD. The primary outcome of the study was the number of patients with IBD who achieved remission (improvement of IBD symptoms and normalisation of the laboratory tests) at the end of the follow-up period.

## Statistical analysis

Data were reviewed for accuracy and integrity and analysed using SPSS Statistics for Windows, V.21.0 (IBM Corp, Armonk, New York, USA). Continuous variables are presented as the mean $\pm$ SD, and categorical variables are expressed as numbers with proportion, n (%). Variables relevant to laboratory data were dichotomised according to prefixed cut-offs, considering the normal reference values. The Student's t-test was performed to compare quantitative variables between two groups of normally distributed data. The  $\chi^2$  test was performed to evaluate the association between qualitative variables. Fisher's exact test with Yates correction was used when cell count was  $<5$ . Responses that have non-applicable values were coded with '-1' and we use the SPSS programme strategy for handling missing values in the analysis. Repeated-measures analysis of variance (ANOVA) was used to test the significance of differences in the means of quantitative variables measured at different times. Multivariate logistic regression analyses were conducted to identify independent risk factors for *H. pylori* infection among patients with IBD. Cox regression analysis (or proportional hazards regression) was used to evaluate the effects of several variables at the time of occurrence of a specified event. Hazard rate ratios (HR) with 95% confidence intervals (CIs) were calculated, and factors associated with IBD flare/remission were thus identified when testing variables with significant differences (significance levels  $<0.05$ ) in the simple logistic regression analyses. Kaplan-Meier analysis was used to estimate the probability of recovery (remission of IBD as the event-of-interest) considering *H. pylori* infection status and treatment option. Recovery-defined remission/improvement in IBD status was based on clinical and laboratory data, whereas censored data defined lack of improvement or flare of the inflammatory condition. Statistical analyses were conducted using two-tailed tests (level of significance  $<0.05$ ).

## RESULTS

### Sociodemographic and clinical characteristics

Patients with IBD (n=182) (n=96 (52.7%) UC and n=86 (47.3%) CD) included 51.7% males, 58.2% married, 51.6% resided in urban areas, 76.9% highly literate, and 82.4% non-smokers. The average age was 27.0 $\pm$ 7.3 years, with the majority ranging from 20 to 35 years. Normal BMI was a predominant feature (59.3%), and 31.9% were overweight. Patients' other sociodemographic characteristics are shown in [table 1](#).

The physical activity scores were comparable between the study participants. However, those without *H. pylori* infection were judged to have a favourable food-habit

**Table 1** Characteristics of the study population

	Patients with IBD		<i>H. Pylori</i> infection in patients with IBD			
	Total (n=182)		Negative (n=92)		Positive (n=90)	
	No	%	No	%	No	%
Type of IBD diagnosed						
Crohn's disease	86	47.3	44	47.8	42	46.7
Ulcerative colitis	96	52.7	48	52.2	48	53.3
Onset of <i>H. pylori</i> infection						
None	92	50.5	92	100	0	0
Few weeks ago	7	3.8	0	0	7	7.8
3–6 months	10	5.5	0	0	10	11.1
6 months–1 year	35	19.2	0	0	35	38.9
>1 year	38	20.9	0	0	38	42.2
History of receiving <i>H. pylori</i> eradication therapy in the past 12 months prior to the study						
No	89	48.9	76	82.6	13	14.4
Yes	93	51.1	16	17.4	77	85.6
Treatment option given						
Conventional	106	58.2	47	51.1	59	65.6
Biological	76	41.8	45	48.9	31	34.4
Sex						
Male	94	51.6	46	50	48	53.3
Female	88	48.4	46	50	42	46.7
Age (years)						
16–<20	20	11	15	16.3	5	5.6
20–<35	136	74.7	62	67.4	74	82.2
35–55	26	14.3	15	16.3	11	12.2
Mean±SD	27.0±7.3		27.6±8.0		26.3±6.5	
Age at IBD diagnosis						
10–>19	69	37.9	35	38	34	37.8
20–<30	83	45.6	46	50	37	41.1
30–45	30	16.5	11	12	19	21.1
Mean±SD	21.6±6.4		21.4±6.3		22.0±6.5	
Residence						
Rural	88	48.4	51	55.4	37	41.1
Urban	94	51.6	41	44.6	53	58.9
Education						
Illiterate	2	1.1	0	0	2	2.2
Read and write	23	12.6	12	13	11	12.2
Primary	4	2.2	4	4.3	0	0
Preparatory	13	7.1	9	9.8	4	4.4
Secondary	44	24.2	24	26.1	20	22.2
University education	96	52.7	43	46.7	53	58.9
Working status						
No	88	48.4	39	42.4	49	54.4
Yes	94	51.6	53	57.6	41	45.6
Occupation						

Continued

Table 1 Continued

	Patients with IBD		<i>H. Pylori</i> infection in patients with IBD			
	Total (n=182)		Negative (n=92)		Positive (n=90)	
	No	%	No	%	No	%
Unemployed	37	20.3	21	22.8	16	17.8
Student	45	24.7	16	17.4	29	32.2
Clerical	2	1.1	2	2.2	0	0
Professional	39	21.4	17	18.5	22	24.4
Housewife	21	11.5	10	10.9	11	12.2
Auxiliary worker	22	12.1	12	13	10	11.1
Farmer	16	8.8	14	15.2	2	2.2
Marital status						
Single	73	40.1	37	40.2	36	40
Married	106	58.2	55	59.8	51	56.7
Widowed	2	1.1	0	0	2	2.2
Divorced	1	0.5	0	0	1	1.1
Socioeconomic standard						
High	58	31.9	24	26.1	34	37.8
Middle	52	28.6	30	32.6	22	24.4
Low	72	39.6	38	41.3	34	37.8
Consanguinity						
No	144	79.1	70	76.1	74	82.2
Yes	38	20.9	22	23.9	16	17.8
History of being breastfed						
No	26	14.3	14	15.2	12	13.3
Yes	156	85.7	78	84.8	78	86.7
Smoking						
Never	150	82.4	75	81.5	75	83.3
Current smoker	26	14.3	13	14.1	13	14.4
Ex-smoker	6	3.3	4	4.3	2	2.2
Age of starting smoking						
Non-smoker	153	84.1	77	83.7	76	84.4
<20 years	17	9.3	10	10.9	7	7.8
20–30 years	12	6.6	5	5.4	7	7.8
>30 years	0	0	0	0	0	0
Smoking other than cigarette						
Never	180	98.9	90	97.8	90	100
Shisha	2	1.1	2	2.2	0	0
BMI categories						
<18.5 (underweight)	3	1.6	2	2.2	1	1.1
18.5–24.99 (normal weight)	108	59.3	58	63	50	55.6
25–29.99 (overweight)	58	31.9	24	26.1	34	37.8
30–39.99 (obese)	13	7.1	8	8.7	5	5.6
Comorbidities						
No	82	45.1	43	46.7	39	43.3
Yes	100	54.9	49	53.3	51	56.7
Diabetes mellitus	10	5.5	4	4.3	6	6.7

Continued

Table 1 Continued

	Patients with IBD		<i>H. Pylori</i> infection in patients with IBD			
	Total (n=182)		Negative (n=92)		Positive (n=90)	
	No	%	No	%	No	%
Hypertension	30	16.5	15	16.3	15	16.7
Bronchial asthma/COPD	15	8.2	11	12	4	4.4
Heart disease	1	0.5	0	0	1	1.1
Renal disease	1	0.5	1	1.1	0	0
Liver disease	1	0.5	0	0	1	1.1
Skin allergy	18	9.9	11	12	7	7.8
Hyperthyroidism	4	2.2	1	1.1	3	3.3
Hypothyroidism	8	4.4	0	0	8	8.9
Other autoimmune diseases	1	0.5	0	0	1	1.1
Others*	27	14.8	8	8.7	19	21.1
Autoimmune diseases						
No	163	89.6	85	92.4	78	86.7
Yes	19	10.4	7	7.6	12	13.3
Medications						
None	13	7.1	12	13	1	1.1
Analgesic (NSAIDs)	12	6.6	3	3.3	9	10
Antidiabetics	6	3.3	3	3.3	3	3.3
Antihypertensives	32	17.6	16	17.4	16	17.8
Corticosteroids	10	5.5	4	4.3	6	6.7
IBD therapy	151	83	70	76.1	81	90
Hormonal contraceptives	2	1.1	0	0	2	2.2
Thyroxin	9	4.9	2	2.2	7	7.8
Others	37	20.3	15	16.3	22	24.4

P value for  $\chi^2$  test. Significant at <0.05.

No history of alcohol or drug abuse was reported.

\*Included chronic sinusitis, vertigo, lumbar disc prolapse, familial dyslipidaemia, haemorrhoids, scleritis, HCV, anaemia, fatty liver, steatosis, psoriasis, peripheral neuropathy, chronic cholecystitis).

*H. pylori*, *Helicobacter pylori*; IBD, inflammatory bowel disease.

score compared with those with *H. pylori* infection (12.2±5.0 vs 10.7±3.8) (online supplemental table S1).

Patients' baseline clinical and laboratory findings are presented in online supplemental table S2. Compared with patients without *H. pylori* infection, infected patients had higher rates of abdominal cramps (91.1% vs 84.8%), abdominal pain (85.6% vs 81.5%), bloating/indigestion (98.9% vs 95.7%), flatulence (100.0% vs 96.7%), diarrhoea (98.9% vs 96.7%), rectal bleeding (73.3% vs 65.2%), fever (33.3% vs 26.1%), chills (10.0% vs 4.3%), infection (23.3% vs 14.1%), fatigue/lack of energy (88.9% vs 68.5%), sick leave/absenteeism (8.9% vs 6.5%) and higher mean CRP (33.0±23.0 vs 28.2±23.9) and ESR (34.6±13.2 vs 33.6±14.1) levels. Gastrointestinal (GIT) endoscopy and colonoscopy revealed features of CD and UC, indicated by superficial ulcerations and mild infiltration.

### *H. pylori* infection among patients with IBD

We detected *H. pylori* infection in 49.5% of patients, including those with UD (48, 50.0%) and CD (42, 48.8%) (OR=1.05 (95% CI: 0.59 to 1.88)), although 85.6% of them reported undergoing *H. pylori* eradication therapy in the past 12 months prior to the study. The infection rate was highest (74, 82.2%) among the age group 20 to <35 years (table 1). Logistic regression analysis revealed that conventional treatment of IBD (OR=1.99 (95% CI: 1.03 to 3.85)), adults aged 20 or <35 years (6.20 (1.74–22.12)) and 35–55 years (11.1 (1.18–104.64)) and mixed food sources (3.12 (1.60–6.06)) predicted *H. pylori* infection (p<0.05) (table 2).

### Assessment of IBD improvement/flare in relation to *H. pylori* infection

The total symptom scores of all patients, as well as the levels of ESR, CRP, haemoglobin and faecal calprotectin,

**Table 2** Predictors of *H. pylori* infection in patients with IBD

Backward stepwise (Wald) logistic regression		B	SE	Wald	df	Sig. (p value)	Exp(B)	95% CI for Exp(B)	
								Lower limit	Upper limit
Step 5	Treatment of IBD								
	Biological treatment	-0.686	0.337	4.14	1	0.042	0.50	0.26	0.98
	Conventional treatment	0.686	0.337	4.14	1	0.042	1.99	1.03	3.85
	Age group (years)								
	16-<20			7.93	2	0.019	Ref		
	20-<35	1.825	0.649	7.92	1	0.005	6.20	1.74	22.12
	35-55	2.408	1.144	4.43	1	0.035	11.11	1.18	104.64
	Food source								
	Homemade			11.48	2	0.003	Ref		
	Restaurant	-0.024	0.915	0.00	1	0.979	0.98	0.16	5.87
	Mixed	1.137	0.339	11.25	1	<0.001	3.12	1.60	6.06
	Constant	0.108	1.015	0.01	1	0.915	1.11		

P value significance at <0.05.

*H. pylori*, *Helicobacter pylori*; IBD, inflammatory bowel disease; Ref, reference category.

significantly and linearly declined throughout the follow-up of all patients, independent of the status of *H. pylori* infection ( $p < 0.05$ ). The values of other parameters (body weight, pulse, BP, white blood cells, platelet count and FBG) fluctuated in a non-linear pattern, although the levels were within normal range. Overall, the changes (effect size) varied with time, because the pattern did not significantly differ relative to *H. pylori* infection (table 3 and Figure S1). Subgroup analyses yielded similar results associated with the type of treatment (conventional, online supplemental table S3 and figure S1 or biological, online supplemental table S4 and figure S1).

#### Factors associated with improvement in IBD symptoms

Cox regression analysis revealed that subjects aged 20–35 years (HR=6.20 (95% CI: 1.74 to 22.12)) and 35–55 years (557.9 (17.4–17 922.8)), high socioeconomic status (2.9 (1.11–7.8)), daily consumption of fibre-rich food (5.1 (1.32–19.5)), occasional consumption of snacks between meals (2.8 (2.5–70.5)) and eating four meals per day (13.3 (1.0–7.7)) were significantly associated with IBD flare ( $p < 0.05$ ). By contrast, eating fruits and vegetables protected against IBD flare (HR=0.001 (95% CI: 0.0002 to 0.02)) (table 4 and online supplemental table S5).

#### Probability of improvement of IBD symptoms in relation to *H. pylori* infection and IBD treatment strategy

Kaplan-Meier analysis revealed that the probabilities of recovery (remission) among the patients after 12 weeks of follow-up were comparable, considering *H. pylori* infection status (0.793 for *H. pylori* negative vs 0.778 for *H. pylori* positive) or IBD treatment option (0.811 for conventional therapy vs 0.750 for biological therapy). The number of patients who recovered from IBD among patients who were *H. pylori* negative was similar to that of patients who were *H. pylori* positive. By contrast, the proportion

of recovered patients with IBD who underwent conventional therapy was higher compared with those administered biological therapy, although the difference was not significant. Thirty-nine subjects did not recover until the end of the study. The results of log-rank, Breslow and Tarone-Ware tests of equality of recovery (remission) did not significantly differ in relation to *H. pylori* infection status or IBD treatment strategy ( $p > 0.05$ ) (table 5 and figure 2).

#### DISCUSSION

Recent improvements in hygienic conditions and socioeconomic status have reduced *H. pylori* infection rates, and this trend accompanies increased IBD incidence in most countries. However, the role of *H. pylori* in IBD is unknown.<sup>2 16 31</sup> Numerous studies found lower *H. pylori* infection rates in patients with CD, UC or both, compared with non-IBD controls, although a few studies did not detect a significant association.<sup>9 10 13 21 31</sup> Recent epidemiological studies, animal experiments, and meta-analyses reveal an inverse correlation between *H. pylori* infection and the onset of IBD onset, suggesting that colonisation by *H. pylori* confers a protective effect against autoimmune diseases.<sup>13 23 32</sup>

To further explain the negative association between *H. pylori* infection and IBD, we conducted a longitudinal study of patients with IBD, with or without *H. pylori* infection, to determine the influence of *H. pylori* infection on patients' responses to conventional versus biological treatment of IBD.

*H. pylori* was detected in approximately 50% of the patients, which is low compared with the prevalence among the population of Egypt, where disease is endemic.<sup>33–36</sup> These findings support the results of studies



**Table 3** Repeated-measures ANOVA of clinical and laboratory findings among patients with IBD during follow-up

Parameter	Repeated measures ANOVA												Between-subject effects							
	Follow-up period (3 Months)						Within subject effects						Linearity (F value)†	P	F	P				
	Baseline	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Multivariate test												
Mean±SD	Mean±SD	Mean±SD	Mean±SD	Mean±SD	Mean±SD	Mean±SD	F*	Wilks' lambda	Partial eta squared	Observed power	Effect of time (T vs state (T×S))	F*	P	Effect size (partial eta squared)‡	Linearity (F value)†	P	F	P		
ESR (mm/hr)	34.6±13.2	30.5±10.9	27.0±10.3	24.2±8.9	20.6±27.3	14.0±5.3	T	96.93	<0.001	0.769	1.000	T	350.0	<0.001	0.660	570.0	<0.001	1.75	0.188	0.010
	33.6±14.1	29.1±11.3	25.2±9.4	21.4±8.6	19.2±6.9	13.0±4.9	T×S	1.156	0.322	0.038	0.448	T×S	0.666	0.538	0.004	0.001	0.974			
CRP (mg/dL)	33.0±23.0	26.4±18.4	22.8±16.1	18.9±13.0	15.9±9.7	10.1±7.2	T	31.74	<0.001	0.521	1.000	T	152.0	<0.001	0.458	181.4	<0.001	2.59	0.109	0.014
	28.2±23.9	22.9±19.5	19.0±15.4	15.9±12.7	13.0±9.4	8.2±4.5	T×S	0.708	0.644	0.024	0.276	T×S	0.788	0.418	0.004	0.848	0.358			
FBG (mg/dL)	94.9±11.1	93.0±10.6	91.6±9.8	94.4±11.5	92.1±9.5	93.7±9.0	T	3.52	0.003	0.108	0.945	T	2.77	0.016	0.015	2.753	0.11	0.974	0.325	0.005
	96.1±11.6	93.0±10.6	95.1±9.3	96.0±13.1	93.7±9.7	95.1±8.4	T×S	1.48	0.187	0.048	0.565	T×S	1.56	0.168	0.009	0.443	0.507			
C-reactive protein (µg/g)	515.0±206.7	314.5±166.3	172.0±139.4	157.4±82.2	74.5±29.3	85.5±66.9	T	253.0	<0.001	0.810	1.000	T	569.4	<0.001	0.760	753.5	<0.001	0.424	0.516	0.002
	517.4±214.4	326.3±166.3	172.0±139.4	157.4±82.2	74.5±29.3	85.5±66.9	T×S	0.157	0.925	0.003	0.078	T×S	0.108	0.854	0.001	0.073	0.787			
Hb (g/dL)	11.0±1.4	11.1±1.3	11.2±1.2	11.5±1.1	11.6±1.0	12.0±0.9	T	49.7	<0.001	0.63	1	T	151.0	<0.001	0.456	279.2	<0.001	0.042	0.837	0.00024
	10.8±1.4	11.0±1.6	11.3±1.1	11.5±1.0	11.7±1.0	12.2±0.75	T×S	3.1	0.007	0.096	0.91	T×S	3.75	0.012	0.02	5.61	0.019			
WBCs (cell/µl)	6621.1±1506.9	6701.1±1349.8	6511.8±1161.0	6597.6±271.7	6625.4±1057.3	6389.2±1131.6	T	4.21	0.001	0.126	0.977	T	7.26	<0.001	0.039	2.44	0.120	14.7	<0.001	0.076
	6420.8±1530.5	6249.0±1385.3	8170.1±1195.3	5890.8±1066.8	5985.9±1022.0	5873.3±979.3	T×S	1.05	0.394	0.035	0.409	T×S	1.18	0.318	0.007	1.65	0.200			
Platelets (x10 <sup>9</sup> /µl)	296.2±3.2	292.3±3.4	287.0±4.2	282.1±3.1	282.5±3.3	284.2±2.1	T	3.23	0.005	0.100	0.922	T	5.12	0.003	0.028	7.37	0.007	0.015	0.904	0.0001
	304.8±61.7	283.0±50.4	279.2±44.3	282.0±48.5	288.1±46.5	284.1±44.2	T×S	1.02	0.415	0.034	0.396	T×S	1.22	0.302	0.007	0.559	0.456			
Total symptom score	20.9±3.1	20.3±3.7	14.2±4.6	5.8±3.1	2.9±3.0	0.7±2.1	T	754.9	<0.001	0.964	1.000	T	1371.1	<0.001	0.890	432	<0.001	0.007	0.932	0.00004
	20.6±3.1	20.4±3.7	13.8±4.6	5.4±3.0	3.4±2.9	0.8±1.6	T×S	0.901	0.496	0.031	0.35	T×S	0.728	0.502	0.004	0.003	0.955			
Body weight (kg)	68.3±11.8	68.3±11.8	69.1±11.7	69.4±11.4	69.4±11.4	69.3±11.9	T	20.34	<0.001	0.411	1.000	T	16.67	<0.001	0.085	0.061	0.805	0.067	0.797	0.0004
	67.6±12.2	67.6±12.1	68.3±12.1	68.0±13.8	68.9±12.1	70.2±12.0	T×S	2.08	0.058	0.067	0.740	T×S	3.95	0.013	0.021	7.73	0.006			
Pulse (BPM)	80.8±5.0	79.9±4.3	78.3±4.0	77.2±4.8	78.3±4.1	78.5±2.8	T	5.36	<0.001	0.155	0.995	T	8.24	<0.001	0.044	6.93	0.009	3.13	0.079	0.017
	80.5±5.6	79.5±5.5	78.9±4.8	78.7±5.0	78.2±5.0	78.3±4.7	T×S	2.87	0.017	0.084	0.856	T×S	3.27	0.007	0.018	6.67	0.011			
Pulse pressure (mmHg)	41.0±5.6	41.3±6.7	39.7±8.9	40.7±8.6	41.1±7.6	39.6±6.9	T	0.729	0.627	0.024	0.284	T	0.759	0.593	0.004	1.69	0.195	1.13	0.29	0.006
	41.5±6.8	40.2±6.8	41.6±7.9	40.9±8.1	41.8±8.5	42.0±9.3	T×S	1.28	0.270	0.042	0.493	T×S	1.201	0.305	0.007	0.286	0.593			

P value is significant <0.05.  
 T, S, T×S are significant *H. pylori* infection.  
 \*F value based on Greenhouse-Geisser test was considered in highlighted cells when Mauchly's test is significant (<0.05).  
 †Significant quadratic effect was considered in highlighted cells when linear effect was insignificant.  
 ‡ANOVA analysis of variance; BPM, beat per minute; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; FBG, fasting blood glucose; Hb, haemoglobin; *H. pylori*, *Helicobacter pylori*; IBD, inflammatory bowel disease; WBCs, white blood cells.



**Table 4** Cox regression analysis of factors associated with IBD flare during follow-up

Backward stepwise (Wald) logistic regression		B	SE	Wald	df	Sig. (p value)	Exp(B)	95% CI for Exp(B)		
								Lower limit	Upper limit	
Step 6	Age (years)									
	16–<20			13.83	2	<0.001	Ref			
	20–<35	1.50	0.71	4.41	1	0.036	4.49	1.11	18.21	
	35–55	6.32	1.77	12.76	1	<0.001	557.92	17.37	17 922.78	
	Socioeconomic standard									
	High	1.08	0.50	4.71	1	0.030	2.94	1.11	7.79	
	Middle	0.68	0.48	1.97	1	0.160	1.97	0.76	5.10	
	Low			4.71	2	0.095				
	Food rich in insoluble fibre									
	Once per week			8.75	2	0.013	Ref			
	2–4 times per week	0.02	0.58	0.00	1	0.973	1.02	0.33	3.18	
	Daily	1.62	0.69	5.61	1	0.018	5.08	1.32	19.49	
	Fruits and vegetables									
	Never			22.20	3	<0.001	Ref			
	Once per week	–7.07	1.63	18.74	1	<0.001	0.001	0.00003	0.02	
	2–4 times per week	–7.61	1.62	22.06	1	<0.001	0.001	0.00002	0.01	
	Daily	–7.47	1.68	19.76	1	<0.001	0.001	0.00002	0.02	
	Number of meals per day									
	Two			10.25	2	0.006	Ref			
	Three	–0.11	0.38	0.08	1	0.780	0.90	0.43	1.89	
	Four	2.59	0.85	9.30	1	0.002	13.33	2.52	70.46	
Snacks between meals										
Never			11.43	2	0.003	Ref				
Occasionally	1.04	0.51	4.07	1	0.044	2.82	1.03	7.72		
Daily	–3.89	2.03	3.69	1	0.055	0.02	0.00	1.08		

P value significance at &lt;0.05.

IBD, inflammatory bowel disease; Ref, reference category.

showing that lower rates *H. pylori* infection of patients with IBD, suggesting an association between *H. pylori* and IBD.<sup>9 21</sup> The rate of *H. pylori* infection is significantly higher among patients with IBD who undergo conventional treatment, which conflicts with studies suggesting that 5-aminosalicylates or sulphasalazine interfere with the adhesion of *H. pylori* to the mucosa and block its proliferation.<sup>22 37–39</sup> For example, the results of multiple studies do not support the conclusion that treatment with sulfasalazine or other drugs such as 5-aminosalicylic acid, thiopurines, steroids and antibiotics influence the colonisation rate of *H. pylori*.<sup>13 40–42</sup> It is worth noting that although the treatment of patients with IBD with anti-TNF- $\alpha$  agents, immunosuppressant and/ or corticosteroid increases the risk of infections, there is no direct evidence that novel therapeutic strategies such as anti-TNF- $\alpha$  and immunosuppressants result in exacerbating or influence the prevalence of *H. pylori* infection. Similar findings were reported by a study of novel therapeutic strategies such as anti-TNF- $\alpha$  treatment.<sup>32</sup>

Here we show that the majority of patients who were *H. pylori* positive with IBD admitted undergoing *H. pylori* eradication therapy during the previous 12 months, which raises questions about the efficacy of eradication therapy or reveals reinfection among this group of patients. Notably, most studies do not report subjects' history of treatment of *H. pylori* infection.<sup>13</sup> It is therefore possible that such patients with IBD were treated for *H. pylori* infection before enrolment, culminating in an incorrectly low rate of *H. pylori* infection.

Accumulating evidence suggests that *H. pylori*, through its ability to regulate the immune response, protects human from diseases with an autoimmune component, including IBD.<sup>43</sup> The results of investigations designed to confirm this possibility are controversial. For example, the heterogeneity among studies accounted for by methods used to diagnose IBD and *H. pylori* infection, study location, study population and the possibility of publication bias limit the validity of this conclusion and raise questions concerning the robustness of their findings.


**Table 5** Kaplan-Meier analysis of the probability of improvement in IBD symptoms in relation to with *H. pylori* infection and IBD treatment strategy

Variable	Group	Case summary	No of events (%)	Censored N (%)	Event time (bimonthly visit)	No of events (recovery*)	No of relapse (recovery*)	No at risk (to recovery*)	Probability of recovering*	Test of equality of recovery*		
										Log rank (Mantel-Cox) P value	Breslow (generalised Wilcoxon)	Tarone-Ware
<i>H. pylori</i> infection in patients with IBD	Negative	n=92	73 (79.3)	19 (20.7)	1	0	2	92	0.000	0.969	0.708	0.833
					2	1	4	91	0.011			
					3	0	5	91	0.011			
					4	14	3	77	0.163			
					5	17	1	60	0.348			
					6	41	4	19	0.793			
	Positive	n=90	70 (77.8)	20 (22.2)	1	0	0	90	0.000	0.893	0.867	0.880
					2	0	3	90	0.000			
					3	2	1	88	0.022			
					4	22	6	66	0.267			
					5	8	6	58	0.356			
					6	38	4	20	0.778			
Treatment of IBD	Conventional	n=106	86 (81.1)	20 (18.9)	1	0	0	106	0.000	0.893	0.867	0.880
					2	0	3	106	0.000			
					3	2	1	104	0.019			
					4	21	5	83	0.217			
					5	16	6	67	0.368			
					6	47	5	20	0.811			
	Biological	n=76	57 (75.0)	19 (25.0)	1	0	2	76	0.000	0.893	0.867	0.880
					2	1	4	75	0.013			
					3	0	5	75	0.013			
					4	15	4	60	0.211			
					5	9	1	51	0.329			
					6	32	3	19	0.750			

p value significant at &lt;0.05.

\*Recovery reflects a state of remission of IBD condition.

*H. pylori*, *Helicobacter pylori*; IBD, inflammatory bowel disease.



**Figure 2** The equality of recovery (remission of IBD symptoms) during the follow-up periods associated with *H. pylori* infection status and IBD treatment strategies.

Here we conducted a prospective study to extended previous work through investigations of the association between *H. pylori* infection and IBD. A potential avenue for extending our study involved broadening the inclusion criteria to gain further insight into local variations of the protective effects of *H. pylori* against IBD. In contrast to previous studies, we added subgroup analysis of *H. pylori* infection and the type of IBD treatment. However, we did not detect a significant relationship between the two conditions. For example, disease course was similar among all patients with IBD regardless of their *H. pylori* infection status or conventional or biological treatment. Moreover, the extent, and severity of IBD increased with a decrease in *H. pylori* infection. We were intrigued by our findings that that the proportion of patients administered conventional therapy who recovered from IBD was higher than those administered biological therapy. This may be explained by the higher rate of *H. pylori* infection among patients with IBD administered conventional therapy or that patients administered biological therapy were refractory to previous conventional therapy and therefore suffered from increased disease severity.

Evidence indicates that IBD is induced through complex interactions between environmental and genetic factors. The growing burden of IBD may serve as a proxy for the hygiene hypothesis and improvements in the sanitation of living conditions, lifestyle and dietary changes, more frequent antibiotic use, enhanced diagnostic methods and heightened awareness of IBD.<sup>1 44 45</sup> Accordingly, we further investigated the role of host and environmental cofactors reported to ameliorate or incite factors for IBD flare (eg, diet, smoking, physical activity, breastfeeding, socioeconomic status, education, occupation, urban vs rural lifestyle and medication).<sup>1</sup> In this context, we were guided by existing studies that recognised differences in potential risk factors or features unique to certain populations, such as the Mediterranean diet. Indeed, dietary factors play a crucial role in disease initiation or relapse,<sup>46</sup> although certain diets such as the Mediterranean diet are purported to protect against IBD.<sup>47–49</sup>

The plant-based, semi-vegetarian Mediterranean diet alleviates symptoms of IBD and maintains patients in remission, potentially through reducing inflammation

and improving the microbiota.<sup>50 51</sup> In our present cohort, patients who were *H. pylori* negative with IBD and those experiencing less flare had a more favourable overall dietary habit score. Consistent with Kakodkar and Mutlu's recommendations,<sup>50</sup> which encourage the consumption of all vegetables and fruits in an IBD diet, we observed a strong protective role on IBD flare of daily and two to three times weekly consumption of vegetables and fruits. Moreover, a recent meta-analysis shows that the beneficial effect of *H. pylori* experienced by Mediterranean populations with IBD is lower compared with residents of East Asian and European regions.<sup>19</sup> Nevertheless, the analysis did not explicitly incorporate dietary information or study the putative beneficial effect of diet as a confounder. Moreover, this positive effect may be attributed to the relative abundance of CagA *H. pylori* in these populations, a strain that produces specific constituents that modulate host immune defences.<sup>52</sup>

Fibre may serve as an anti-inflammatory component of IBD treatment, although a converse effect can occur.<sup>1</sup> Our Cox regression analysis revealed that daily consumption of foods rich in insoluble fibre, such as whole bread, cereals, beans, peas, wheat, oat, artichoke, cabbage, cauliflower, broccoli, dried herbs and spices, significantly increased the risk of IBD flare, particularly in patients who consume four daily meals interspersed with occasional snacks.

In agreement with Gentschew *et al*,<sup>53</sup> trans-fat consumption was associated with a higher probability of IBD flare, although this was not a variable included in our final model. Although our findings suggest a role for diet in IBD flare, its effect is questionable because of the limitations of recall bias and multifactorial exposures. Moreover, patients with IBD may alter their dietary habits in response to symptoms that vary with disease activity, which requires further direct research into the role of diet in IBD.

Variations in the protective effects of *H. pylori* on IBD may be explained by socioeconomic factors. For example, here we show that patients with IBD with higher socioeconomic status and mainly urban residents had a higher chance of disease flares. Moreover, the frequency of *H. pylori* infection did not significantly vary in association with socioeconomic status. These findings support the argument that factors associated with an urban lifestyle and industrialisation influence risk of IBD. Furthermore, the rate of gastric colonisation by *H. pylori* was significantly higher in adults aged >20 years, although there was no significant difference in the average age of IBD onset between *H. pylori*-positive and *H. pylori*-negative groups. This age group experienced a higher frequency of disease flares. These findings may be explained by patients' histories of comorbidities or lifestyle, which affect the occurrence of IBD. Demographic variables other than age did not exert detectable effects.

The findings of this study must be interpreted in view of its limitations. First, we did not test gastric biopsies for *H. pylori*, which may have decreased the disease prevalence

rate. However, this would incur the burdens of an ethically questionable invasive procedure. A urea breath test may serve as a better alternative, although we did not have access to this test in our centres. Second, the small sample size was a major limitation and may have influenced the estimation of effect size. Third, the trend of decreased *H. pylori* infection in patients administered biological therapy coincided with increased severity of IBD, which should be investigated by a larger, statistically robust randomised controlled trial. Moreover, our results merit reassessment in a cohort of patients from a background population with a low prevalence of *H. pylori* that includes detailed information about eradication treatment and administration of other antibiotics. Fourth, a causal relationship between *H. pylori* infection and IBD cannot be established through an uncontrolled study (control group without IBD), and further large-scale prospective studies are required. Thus, studies are warranted to investigate the effects of eradication of *H. pylori* on the development of IBD combined with analyses of environmental exposures, hygiene diet, physical activity and intestinal microbiota as significant confounders. An ideal study would be prospective and initiated when IBD is diagnosed.

## CONCLUSIONS

Together, the findings of our present analysis of the association between IBD and *H. pylori* infection are inconclusive, and further studies are required. Thus, much remains to be learnt about the causes of IBD and whether specific environmental exposures influence the development of disease and its course.

**Acknowledgements** We would like to acknowledge the study participants for accepting to participate in the study.

**Contributors** EWAE-W was the study guarantor, helped in conceptualisation, developed the theoretical framework and study design, took the lead for overall direction and planning of the study implementation, performed data curation, statistical analysis and interpretation of data, did major contribution to writing, revised and approved final version of the manuscript. EIY was involved in study implementation and recruitment of the study participants, data collection, clinical evaluation and follow up, analysis and interpretation of data, contributed to the writing of the manuscript, revised and approved final version of the of the manuscript. EH supervised the study implementation and data collection, facilitated the recruitment of the study participants, performed clinical evaluation and follow up, data curation, contributed to the writing of the manuscript, revised and approved final version of the manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

**Patient consent for publication** Consent obtained directly from patient(s)

**Ethics approval** The study was approved by the institutional review board and the ethics committee of the High Institute of Public Health affiliated with Alexandria University, Egypt [Ref no. 603-2019]. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. All data are fully available without restriction from the corresponding

author at ekram.wassim@alexu.edu.eg and through the public data repository <http://www.opendatarepository.org>.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iD

Ekram W. Abd El-Wahab <http://orcid.org/0000-0003-4220-5859>

## REFERENCES

- 1 Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. *Clin Epidemiol* 2013;5:237.
- 2 Kamm MA. Rapid changes in epidemiology of inflammatory bowel disease. *Lancet* 2017;390:2741–2.
- 3 Bloomfield SF, Stanwell-Smith R, Crevel RWR, et al. Too clean, or not too clean: the hygiene hypothesis and home hygiene. *Clin Exp Allergy* 2006;36:402–25.
- 4 Koloski N-A, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. *World J Gastroenterol* 2008;14:165–73.
- 5 Frolkis A, Dieleman LA, Barkema HW. Environment and the inflammatory bowel diseases. *Canadian Journal of Gastroenterology and Hepatology* 2013;27:e18–24.
- 6 Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. *Gastroenterol Hepatol* 2010;6:339.
- 7 Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. *World J Gastroenterol* 2014;20:12781–808.
- 8 Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. *Gastroenterology* 2017;153:420–9.
- 9 Rokkas T, Gisbert JP, Niv Y, et al. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. *United European Gastroenterol J* 2015;3:539–50.
- 10 Wu X-W, Ji H-Z, Yang M-F, et al. Helicobacter pylori infection and inflammatory bowel disease in Asians: a meta-analysis. *World J Gastroenterol* 2015;21:4750–6.
- 11 Lundgren A, Suri-Payer E, Enarsson K, et al. Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. *Infect Immun* 2003;71:1755–62.
- 12 Kao JY, Rathinavelu S, Eaton KA, et al. Helicobacter pylori-secreted factors inhibit dendritic cell IL-12 secretion: a mechanism of ineffective host defense. *Am J Physiol Gastrointest Liver Physiol* 2006;291:G73–81.
- 13 Luther J, Dave M, Higgins PDR, et al. Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. *Inflamm Bowel Dis* 2010;16:1077–84.
- 14 Kayali S, Gaiani F, Manfredi M, et al. Inverse association between Helicobacter pylori and inflammatory bowel disease: myth or fact? *Acta Biomed* 2018;89:81–6.
- 15 Lin K-D, Chiu G-F, Waljee AK, et al. Effects of anti-Helicobacter pylori therapy on incidence of autoimmune diseases, including inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2019;17:31390–9.
- 16 Yu Y, Zhu S, Li P, et al. Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract. *Cell Death Dis* 2018;9:961.
- 17 Shinzaki S, Fujii T, Bamba S, et al. Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease

- activity of patients with inflammatory bowel disease. *Intest Res* 2018;16:609–18.
- 18 Burisch J, Jess T. Does eradication of *Helicobacter pylori* cause inflammatory bowel disease? *Clin Gastroenterol Hepatol* 2019;17:1940–1.
  - 19 Imawana RA, Smith DR, Goodson ML. The relationship between inflammatory bowel disease and *Helicobacter pylori* across East Asian, European and Mediterranean countries: a meta-analysis. *Ann Gastroenterol* 2020;33:485–94.
  - 20 Yazdanbod A, Salimian S, Habibzadeh S, *et al.* Effect of *Helicobacter pylori* eradication in Iranian patients with functional dyspepsia: a prospective, randomized, placebo-controlled trial. *Arch Med Sci* 2015;11:964–9.
  - 21 Rosania R, Von Arnim U, Link A, *et al.* *Helicobacter pylori* eradication therapy is not associated with the onset of inflammatory bowel diseases. A case-control study. *J Gastrointestin Liver Dis* 2018;27:119–25.
  - 22 el-Omar E, Penman I, Cruikshank G, *et al.* Low prevalence of *Helicobacter pylori* in inflammatory bowel disease: association with sulphasalazine. *Gut* 1994;35:1385–8.
  - 23 Lee HS, Park S-K, Park DI. Novel treatments for inflammatory bowel disease. *Korean J Intern Med* 2018;33:20–7.
  - 24 Jung H-K. Rome III criteria for functional gastrointestinal disorders: is there a need for a better definition? *J Neurogastroenterol Motil* 2011;17:211–2.
  - 25 Ogedegbe G, Pickering T. Principles and techniques of blood pressure measurement. *Cardiol Clin* 2010;28:571–86.
  - 26 Muntner P, Shimbo D, Carey RM, *et al.* Measurement of blood pressure in humans: a scientific statement from the American heart association. *Hypertension* 2019;73:e35–66.
  - 27 Casadei K, Kiel J. *Anthropometric measurement*. Treasure Island (FL): StatPearls, 2019.
  - 28 McClatchey KD. *Clinical laboratory medicine*. 2nd ed. Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo: Lippincott Williams & Wilkins, 2002.
  - 29 Magro F, Langner C, Driessen A, *et al.* European consensus on the histopathology of inflammatory bowel disease. *J Crohns Colitis* 2013;7:827–51.
  - 30 El-Gilany A, El-Wehady A, El-Wasify M. Updating and validation of the socioeconomic status scale for health research in Egypt. *East Mediterr Health J* 2012;18:962–8.
  - 31 Papamichael K, Konstantopoulos P, Mantzaris GJ. *Helicobacter pylori* infection and inflammatory bowel disease: is there a link? *World J Gastroenterol* 2014;20:6374–85.
  - 32 Zhong Y, Zhang Z, Lin Y, *et al.* The Relationship Between *Helicobacter pylori* and Inflammatory Bowel Disease. *Arch Iran Med* 2021;24:317–25.
  - 33 Bassily S, Frenck RW, Mohareb EW, *et al.* Seroprevalence of *Helicobacter pylori* among Egyptian newborns and their mothers: a preliminary report. *Am J Trop Med Hyg* 1999;61:37–40.
  - 34 Naficy AB, Frenck RW, Abu-Elyazeed R, *et al.* Seroepidemiology of *Helicobacter pylori* infection in a population of Egyptian children. *Int J Epidemiol* 2000;29:928–32.
  - 35 Mohammad MA, Hussein L, Coward A, *et al.* Prevalence of *Helicobacter pylori* infection among Egyptian children: impact of social background and effect on growth. *Public Health Nutr* 2008;11:230–6.
  - 36 Galal YS, Ghobrial CM, Labib JR, *et al.* *Helicobacter pylori* among symptomatic Egyptian children: prevalence, risk factors, and effect on growth. *J Egypt Public Health Assoc* 2019;94:17.
  - 37 Stenson WF, Mehta J, Spilberg I. Sulphasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. *Biochem Pharmacol* 1984;33:407–12.
  - 38 Mantzaris GJ, Archavlis E, Zografos C, *et al.* Low prevalence of *Helicobacter pylori* in inflammatory bowel disease: association with sulfasalazine. *Am J Gastroenterol* 1995;90:1900.
  - 39 Piodi LP, Bardella M, Rocchia C, *et al.* Possible protective effect of 5-aminosalicylic acid on *Helicobacter pylori* infection in patients with inflammatory bowel disease. *J Clin Gastroenterol* 2003;36:22–5.
  - 40 Halme L, Rautelin H, Leidenius M, *et al.* Inverse correlation between *Helicobacter pylori* infection and inflammatory bowel disease. *J Clin Pathol* 1996;49:65–7.
  - 41 Guslandi M, Fanti L, Testoni PA. *Helicobacter pylori* seroprevalence in Crohn's disease: lack of influence by pharmacological treatment. *Hepatogastroenterology* 2002;49:1296–7.
  - 42 Song MJ, Park DI, Hwang SJ, *et al.* [The prevalence of *Helicobacter pylori* infection in Korean patients with inflammatory bowel disease, a multicenter study]. *Korean J Gastroenterol* 2009;53:341–7.
  - 43 van Amsterdam K, van Vliet AHM, Kusters JG, *et al.* Of microbe and man: determinants of *Helicobacter pylori*-related diseases. *FEMS Microbiol Rev* 2006;30:131–56.
  - 44 Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. *Gastroenterology* 2004;126:1504–17.
  - 45 Thia KT, Loftus EV, Sandborn WJ, *et al.* An update on the epidemiology of inflammatory bowel disease in Asia. *Am J Gastroenterol* 2008;103:3167–82.
  - 46 Zallot C, Quilliot D, Chevaux J-B, *et al.* Dietary beliefs and behavior among inflammatory bowel disease patients. *Inflamm Bowel Dis* 2013;19:66–72.
  - 47 Marlow G, Ellett S, Ferguson IR, *et al.* Transcriptomics to study the effect of a Mediterranean-inspired diet on inflammation in Crohn's disease patients. *Hum Genomics* 2013;7:24.
  - 48 Haskey N, Gibson DL. An examination of diet for the maintenance of remission in inflammatory bowel disease. *Nutrients* 2017;9:259.
  - 49 Reddavid R, Rotolo O, Caruso MG, *et al.* The role of diet in the prevention and treatment of inflammatory bowel diseases. *Acta Biomed* 2018;89:60–75.
  - 50 Kakodkar S, Mutlu EA. Diet as a therapeutic option for adult inflammatory bowel disease. *Gastroenterol Clin North Am* 2017;46:745–67.
  - 51 Chiba M, Ishii H, Komatsu M. Recommendation of plant-based diets for inflammatory bowel disease. *Transl Pediatr* 2019;8:23–7.
  - 52 Tepler A, Narula N, Peek RM, *et al.* Systematic review with meta-analysis: association between *Helicobacter pylori* CagA seropositivity and odds of inflammatory bowel disease. *Aliment Pharmacol Ther* 2019;50:121–31.
  - 53 Gentschew L, Ferguson LR. Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. *Mol Nutr Food Res* 2012;56:524–35.